Last December 2022, Mikrobiomik signed a framework collaboration agreement with the Ramón y Cajal Institute for Health Research -IRYCIS-, with the intention of joining forces in the research and co-development of therapeutic innovations related to the human microbiota.
For IRYSIS, research and innovation in the field of microbiota is a transversal axis within its new strategic plan, while for Mikrobiomik, the signing of this framework agreement is a major achievement within its strategic policy of public-private collaborations.
The aim of this collaboration is to bring to the clinic disruptive research projects that, in the future, may provide innovative therapeutic solutions for patients with diseases without an effective therapeutic alternative. Dr. Rosa del Campo, pioneer of intestinal microbiota transplantation in Spain, will lead the different projects to be launched, contributing her extensive experience in the field of human microbiota research. At the same time, Mikrobiomik is already sharing the design of the first clinical trial of its investigational biologic medicine MBK-01, because of the signing of this agreement.
The company, which is located at the BIC BIZKAIA building, celebrates this milestone, which comes along with a period of extraordinary growth and development registered during 2022, with higher expectations for 2023.